Method of administering high-dose, oral magnesium for treatment of chronic pain syndromes or erythromelalgia

a magnesium and chronic pain technology, applied in the field of oral pharmaceuticals, can solve the problems of ineffective oral dosing at pharmacologic levels, inability to use higher oral doses, and inability to accurately predict the effect of oral dosing,

Inactive Publication Date: 2005-06-09
COHEN JAY S
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the results from various studies have not been unequivocal.
The use of higher oral doses has typically been precluded because of magnesium's tendency to provoke diarrhea in many patients when administered orally.
Where the condition being treated is chronic, this is impractical.
However oral dosing at pharmacologic levels has heretofore been ineffective due to the inability of patients to tolerate such a regimen.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0006] Thirteen patients took nonprescription magnesium oxide (MgO2) or magnesium-protein (Mg-protein) products in gradually escalating and divided doses totaling 0.6-5 grams / day elemental magnesium under their physicians' supervision. One patient then took 50%, intravenous-quality magnesium sulfate (MgSO4) orally and reached doses of 12 grams MgSO4 / day. Adjusting dose increases to individual tolerance, 8 of the 13 patients obtained substantial pain reduction and improvement in other symptoms with few adverse effects. Over a period of eight months, one patient, who had been bedridden, obtained nearly complete remission and has resumed many normal activities. All patients had been refractory to previous therapies.

[0007] The preferred magnesium treatment uses a magnesium compound in solution, such as intravenous grade MgSO4 or MgCl in water or dextrose solution. Other magnesium compounds effective in the present invention include magnesium acetate, magnesium carbonate, magnesium citr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
refractoryaaaaaaaaaa
timeaaaaaaaaaa
frequencyaaaaaaaaaa
Login to view more

Abstract

A method of treating patients, particularly for pain and/or symptoms of erythromelalgia, and other neurovascular or neuropathic disorders, etc. involves administering high doses of magnesium. The magnesium is introduced through several daily administrations, totaling approximately 2-12 times the RDA for magnesium. These higher levels are achieved through increasing daily dosage amounts gradually in response to patient tolerance and until beneficial results are seen. Total magnesium intake is divided over several doses per day and taken with copious amounts of water.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application claims the benefit of U.S. provisional patent application Ser. No. 60 / 334,729, filed Nov. 15, 2001.FIELD OF THE INVENTION [0002] This invention is in the field of oral pharmaceuticals, and especially in pain management. BACKGROUND [0003] Magnesium is the seventh most plentiful element in the human body and the most common intracellular divalent cation. A cofactor in hundreds of enzymatic processes, including all enzymes utilizing adenosine triphosphate, magnesium's multiple physiologic effects have been recognized for decades. Clinical studies have suggested that magnesium, as a pharmacologic agent, may be beneficial in many disorders including asthma, cardiac arrhythmias, eclampsia, headaches including migraines, hypertension, mania, mitral valve prolapse, muscle cramps, pain syndromes, various menstrual symptoms, seizures, tetanus, and vasospastic disorders. However, the results from various studies have not been uneq...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K33/06A61K33/08A61K33/14
CPCA61K33/06A61K33/08Y10S514/905Y10S514/867Y10S514/964A61K33/14
Inventor COHEN, JAY S.
Owner COHEN JAY S
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap